To assess the therapeutic potential of IGF-Trap when administered systemically in conjunction with rTMS in a mouse glioma model, we injected mice intra-cranially with 105 luciferase+ GL261 cells and randomized mice 3 days later for the following four treatment groups: (1) mice treated with vehicle only (PBS); (2) mice treated with vehicle immediately after TMS administration; (3) mice injected intravenously with 10 mg/kg IGF-Trap alone; and (4) mice injected with the same dose of IGF-Trap immediately following TMS administration. The gene discussed is IGF1; the disease is central nervous system cancer.